Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partially-blinded, active-controlled, multicenter Phase 2 trial of iscalimab versus tacrolimus in kidney transplant recipients
2017-003607-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iscalimab in kidney transplant, kidney allograft rejection, Immune disorder, sponsored by Novartis. Started Jun 2018; status: completed.
02
Drugs
iscalimab
03
Conditions
kidney transplantkidney allograft rejectionImmune disorder
Beyond the preview
Go deeper on 2017-003607-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003607-22.